The Implantable Subcutaneous String Defibrillator (ISSD), an innovative subcutaneous cardioverter defibrillator for a new paradigm in cardiac rhythm management.

Projektinformationen

ISSD

ID Finanzhilfevereinbarung: 823081

DOI

10.3030/823081

Projekt abgeschlossen

EK-Unterschriftsdatum 20 Juni 2018

Startdatum 1 Juli 2018

Enddatum 31 März 2021

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 3 519 750,00

EU-Beitrag

€ 2 463 825,00

Koordiniert durch

NEWPACE LTD
Israel

Periodic Reporting for period 3 - ISSD (The Implantable Subcutaneous String Defibrillator (ISSD), an innovative subcutaneous cardioverter defibrillator for a new paradigm in cardiac rhythm management.)

Berichtszeitraum: 2020-06-01 bis 2021-03-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Sudden Cardiac Arrest (SCA) is a life-threatening heart condition and one of the most common causes of death in developed countries. It claims more than 350,000 lives per annum in Europe1 and about 95% of people who have SCA die before they reach the hospital. Ventricular Fibrillation is the major cause of SCA and the only effective treatment for it is to prompt electrical defibrillation. There are currently two different implantable technologies to prevent SCAs: 1) Transvenous Implantable Cardioverter-Defibrillators (TV-ICDs), which are implanted under the skin with leads that snake through veins into the heart and are attached to the heart ventricles or atria; and 2) Subcutaneous Implantable Cardioverter-Defibrillators (S-ICD), which also have generators and leads but avoiding leads within the heart, being implanted subcutaneously in whole with no leads within the heart. However, each of these technologies are mired with problems including patient discomfort and as in the case of the S-ICD, a big surgical pocket at implant, and negative impact due to the ICD relatively large generator´s size, the need to replace their batteries every 5-7 years which requires a new replacement operation as well as use of intensive fluoroscopy with occasional lead extractions. NewPace has developed the Implantable Subcutaneous String Defibrillator (ISSD), to address the need for better patient outcomes due to SCA, providing more reliable and safe cardiac rhythm management. The overall objectives of the project are to complete development of the ISSD device, undertaking a series of preclinical tests to confirm its safety and effectiveness, and eventually validating it through a clinical trial with European medical centres. Completion of these objectives will result in a product that is ready for the market.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

NewPace has been focused on finalising the ISSD design and internal testing, before performing the verification & validation testing. In additon to advancing the product's market readiness NewPace has engaged in a number of business development activties that has included participating in events worldwide to engage stakeholders and maintain its IP management strategy that has involved the filing of new patents during the 1st reporting period.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

The ISSD will provide the following key benefits: (1) Subcutaneous: implanted subcutaneously with no leads within the heart; (2) Unitary and flexible: totally integrated (no can, nor leads) and flexible string shape device; (3) Rechargeable: requires one hour/once in a year wireless recharge, designed for 10 years before replacement; (4) Smart phone connectivity: low energy Bluetooth communication (BLE) providing remote monitoring functionalities using a simple smart phone app.

Figure 1

Figure 2